|
Search
Collections
Benchmarks
Upload document
Product
C. difficile investigational vaccine based on the F2 antigen
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 clinical trial
1 indication
Indication
Clostridium Infections
Clinical trial
A Phase I, Single-center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK's Clostridium Difficile Investigational Vaccine Based on the F2 Antigen With or Without AS01B Adjuvant, When Administered Intramuscularly According to a 0, 1-month Schedule to Healthy Adults Aged Between 18-45 Years and Between 50-70 Years, Followed by an Additional Dose Administered in a Partial Blind Manner Within an Interval of Approximately 15 Months After Dose 2, in a Subcohort of Subjects Aged 50-70 Years
Status: Completed
, Estimated PCD: 2022-05-10